Dr. Harvey Karpo

Dr. Karpo graduated the University of Pittsburgh in 1971 with a B.S. in Chemistry and the Pennsylvania College of Podiatric Medicine, now the Temple University College of Podiatric Medicine, in 1975 with the degree of DPM, Doctor of Podiatric Medicine. He completed a residency in Podiatric Medicine and Surgery at Kennedy Hospital in Washington Township in 1976.

Dr. Karpo is Board Certified in Podiatric Orthopedics and is a Fellow of the American College of Foot and Ankle Orthopedics and Medicine and a member of the American Diabetes Association.

He has been an active member of the New Jersey Podiatric Medical Society for many years and served as President of that organization from 2003-2004 and currently serves as a member of the Board of Trustees.

Currently in private practice in Woodbury at 649 North Broad Street, Dr. Karpo specializes in the non-surgical treatment of foot problems and stresses the importance of all aspects of preventative foot care, especially in the diabetic patient.

He has been on staff, and treating patients at Pitman Manor in Pitman, NJ since January, 1978 and is married to Agnes, his boss and office manager.

Wanted to be a stand-up comic but had flat feet!

Listen to Diabetes Living Today interview with Dr. Harvey Karpo

February 1, 2012 ~ Healthy Feet For The Diabetic with Podiatrist Dr. Harvey Karpo

Diabetes Living Today® radio program, provides listeners with education, inspiration and motivation to live healthy and well with diabetes. Whether you have diabetes or know someone who does Diabetes Living Today® radio program offers experience, insight, education and tips to manage life with diabetes. Through interviews, including “World Class” Research Scientist, physicians and people living with diabetes, living well tips and questions from the listening audience, host Kitty Castellini and Endocrinologist Dr. Joseph J. Fallon, Jr. are there every step of the way to offer guidance, advice, and most of all, support.

This week Kitty and Dr. Fallon will host their No Sugar Added®  “Open Forum.”

Listen to Diabetes Living Today®

January 31, 2012 ~ Diabetes Living Today® ~ No Sugar Added® Open Forum

Diabetes Living Today® radio program, provides listeners with education, inspiration and motivation to live healthy and well with diabetes. Whether you have diabetes or know someone who does Diabetes Living Today® radio program offers experience, insight, education and tips to manage life with diabetes. Through interviews, including “World Class” Research Scientist, physicians and people living with diabetes, living well tips and questions from the listening audience, host Kitty Castellini and Endocrinologist Dr. Joseph J. Fallon, Jr. are there every step of the way to offer guidance, advice, and most of all, support.

This week Kitty and Dr. Fallon will host their No Sugar Added®  “Open Forum.”

Listen to Diabetes Living Today®

January 25, 2012 ~ Diabetes Living Today® ~ No Sugar Added® Open Forum

Dr. Howard M. Weinberg, DO, FACC

Dr.  Howard Weinberg is a private practice cardiologist with South Jersey Heart Group, P.C. (SJHG).  South Jersey Heart Group, P.C. includes fifteen cardiologist serving Glouster, Camden and Burlington County.  Dr. Weinberg completed his residency at Albert Einstein Medical Center and his fellowship in Cardiology at Seton Hall University. He is board certified in cardiology and nuclear cardiology and has been treating patients with cardiovascular disease for fifteen years. Dr. Weinberg has served as a board member for American Heart Association of Glouster County and is a board member of The Catastrophic Illness in Children Relief Fund for the State of New Jersey. Dr. Weinberg has been married for eighteen years and has three boys ages 16, 14 and 11. Dr. Weinberg enjoys spending time with his family and coaching his son’s ice hockey teams.

Listen to Diabetes Living Today®

January 24, 2012 ~ Diabetes and Heart Disease with Cardiologist Dr. Howard M. Weinberg

Due to an overwhelming request to rebroadcast Dr. Gerald I. Shulman live on the radio we will do so today.  Kitty Castellini & Dr. Joseph J. Fallon, Jr. will return next week.

Gerald I. Shulman, M.D., Ph.D., F.A.C.P.

Investigator, Howard Hughes Medical Institute

George R. Cowgill Professor of Physiological Chemistry

Professor of Medicine and Cellular & Molecular Physiology

Yale University School of Medicine

Dr. Shulman is the George R. Cowgill Professor of Physiological Chemistry Medicine and Cellular & Molecular Physiology at Yale University as well as an Investigator of the Howard Hughes Medical Institute. He is also Associate Director of the Yale Diabetes-Endocrinology Research Center and Associate Director of the Yale Medical Scientist Training Program. Dr. Shulman completed his undergraduate studies in biophysics at the University of Michigan, and he received his M.D. and Ph.D. degrees from Wayne State University. Following internship and residency at Duke University Medical Center, he did an endocrinology fellowship at the Massachusetts General Hospital and additional postdoctoral work in molecular biophysics and biochemistry at Yale before joining the faculty at Harvard Medical School. He was subsequently recruited back to Yale and has remained there ever since.

Dr. Shulman has pioneered the use of magnetic resonance spectroscopy (MRS) to non-invasively examine intracellular glucose and fat metabolism in humans. His work has been recognized with numerous honors and awards including the Outstanding Investigator Award from the American Federation for Clinical Research, the Diabetes Care Research Award from the Juvenile Diabetes Research Foundation, the Novartis Award in Diabetes, the Outstanding Scientific Achievement Award and the Distinguished Clinical Scientist Award from the American Diabetes Association and the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.

Dr. Shulman has been elected to the Association of American Physicians, Fellow of the American Association for the Advancement of Science, the Institute of Medicine and the National Academy of Sciences.

Listen to Diabetes Living Today® interview with Dr. Gerald I. Shulman

November 30, 2011 ~ Dr. Gerald I. Shulman, Yale University School of Medicine on “Insulin Resistance, Obesity and Type 2 Diabetes

From fried chicken to mac and cheese casseroles, Paula Deen has made her mark on the culinary world – and in the homes of fans – with recipes that don’t skimp on cheese, cream and sugar. Not to mention butter … whole sticks of it.

And even as she reveals that she is living with Type 2 Diabetes, she says it won’t stop her from eating the way she wants.

“I was determined to share my positive approach and not let diabetes stand in the way of enjoying my life,” Deen said Tuesday in a release announcing her launch of Diabetes in a New Light™, geared toward finding “simple ways” to manage challenges of the disease.

“I’m excited to team up with Novo Nordisk on this initiative to show others that managing diabetes does not have to stop you from enjoying the things you love.”

The National Enquirer first reported Deen’s diabetes in April 2010, but she never confirmed or denied the diagnosis until now. She turns 65 Thursday.

The Food Network chef with the folksy Southern drawl – and a tendency to address her fans as “Hey, y’all” – has been famously criticized for her cooking techniques. Just last summer, fellow celeb chef Anthony Bourdain called her the “most dangerous person to America” who’s “proud of the fact that her food is f—— bad for you.”

And as news leaked she was making the announcement regarding her health, Bourdain was inundated with people “looking for quotes.” And he says he “takes no pleasure” in her news, telling Eater.com, he suspects she’s known for a long time and been looking for a way “to position herself.”

“When your signature dish is hamburger in between a doughnut, and you’ve been cheerfully selling this stuff knowing all along that you’ve got Type 2 Diabetes … It’s in bad taste if nothing else,” he said. “How long has she known? I suspect a very long time.”

Deen, it was also revealed in the release, takes Victoza – a once-daily, non-insulin injection – and continues to “make lifestyle adjustments, including lightened-up versions of her favorite recipes.”

Diabetes Living Today® radio program, provides listeners with education, inspiration and motivation to live healthy and well with diabetes. Whether you have diabetes or know someone who does Diabetes Living Today® radio program offers experience, insight, education and tips to manage life with diabetes. Through interviews, including “World Class” Research Scientist, physicians and people living with diabetes, living well tips and questions from the listening audience, host Kitty Castellini and Endocrinologist Dr. Joseph J. Fallon, Jr. are there every step of the way to offer guidance, advice, and most of all, support.

This week Kitty and Dr. Fallon will host their No Sugar Added®  “Open Forum.”

Listen to Diabetes Living Today®

January 17, 2012 ~ Diabetes Living Today® ~ No Sugar Added® Open Forum

The treatment, which combines a patient’s immune system cells with stem cells from a donor’s cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.

Although the treatment didn’t wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.

“Our study brings a new hope for people with type 1 diabetes. If we can control the autoimmunity, we may reverse the diabetes. We showed that the islets 1/8cells3/8 can start to work again,” said Dr. Yong Zhao, an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Illinois at Chicago.

This treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.

“It’s quite remarkable that this approach, based on the re-education of immune cells, might work so well. The concept is very intriguing, and the treatment seems to be so simple and so safe,” said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute, University of Miami School of Medicine.

But he’s also “reasonably cautious,” he said. “The follow-up is long, up to 40 weeks, but it’s not long enough to declare victory against diabetes yet,” said Inverardi.

Also, he noted that the study involved only 15 Chinese people, and that type 1 diabetes is a bit different in that population. He said he’d like to see larger studies with a more diverse population, followed for a longer time.

Results of the study were published online Jan. 9 in the journal BMC Medicine.

Type 1 diabetes, an autoimmune disease, occurs when the body’s immune system cells mistakenly attack the insulin-producing (beta) cells in the pancreas. Because their beta cells don’t produce enough or any insulin, people with type 1 diabetes have to replace the lost insulin through injections to survive.

Stopping that autoimmune attack appears to be crucial to any treatment that hopes to cure or reverse type 1 diabetes.

Zhao’s team developed a completely new approach. They take blood from a patient and separate out the immune system cells (lymphocytes). They briefly expose those cells to stem cells from umbilical cord blood from an unrelated infant and return the lymphocytes alone to the patient’s body. The researchers have dubbed this “Stem Cell Educator Therapy,” because while exposed to the stem cells, the lymphocytes seem to relearn how they should behave.

The study participants, who were 15 to 41 years old, had had type 1 diabetes for an average of nine years. Six had some residual beta cell function and six did not. Both groups were given stem cell educator therapy. The other three people served as the control group.

The researchers measured C-peptide, a protein fragment that’s a byproduct of insulin production, and found that the educator therapy group had improved levels of C-peptide at 12 weeks. These levels continued to improve until 24 weeks, and remained stable through the follow-up at 40 weeks. There were no changes in C-peptide in the control group.

The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.

“That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas. If these data are confirmed, this is a very provocative and remarkable finding,” Inverardi said.

The average hemoglobin A1C level dropped 1.06 percent for those with residual beta cell function and 1.68 percent for those without beta cell function. A1C levels measure average blood sugar levels over two to three months, and people with type 1 diabetes are advised to maintain A1C levels below 7 percent. A drop of 1 percent in A1C levels can reduce the risk of complications.

This was an initial clinical trial designed to test for safety. Zhao said that in future trials he hopes that with additional treatments people might get off insulin altogether.

But, even if that’s not possible, the recovery of some beta cell function would be welcome news. “In the absence of complete remission, there are very sizable advantages to having some beta cell function,” Inverardi noted.

Both experts said the treatment appears safe, with no risk of rejection. No significant side effects were reported during the trial, other than some arm soreness where blood was taken and returned.

Innovative, small, no code device will be available to people with diabetes in the U.S. in first half of 2012

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the

U.S. Food and Drug Administration (FDA) for its Accu-Chek® Nano SmartView blood glucose

monitoring system. The new Accu-Chek Nano meter, which is smaller than a standard credit card, employs a large brilliant backlit display and does not require any manual coding or code key for enhanced ease of use. It also offers improved functions such as customizable test reminders, preand postmeal markers and average glucose calculation. The Accu-Chek Nano meter uses Accu-Chek® SmartView test strips and will be available to customers in the first half of 2012.

“We are very excited to bring this latest blood glucose monitoring technology to the United States,”said Luc Vierstraete, Global Head of Roche Diabetes Care. “The Accu-Chek Nano meter is the newest advancement in Roche’s more than 35-year commitment to bring state-of-the-art innovations to people with diabetes and their caregivers, and continues our promise to enabling optimal diabetes management. This new system will help us to further leverage and enhance our position in this important market.”

According to the 2011 National Diabetes Fact Sheet published by the Centers for Diseases Control and Prevention, more than 25 million people in the US live with diabetes. However, seven million are currently undiagnosed and 1.9 million new cases of diabetes were diagnosed in people aged 20 years and older in 2010. It is also estimated that 79 million people live with pre-diabetes in the US.

“The Accu-Chek Nano blood glucose meter will appeal to those who prefer a small, discreet meter with maximum performance and is Roche Diabetes Care’s latest innovation aimed at enabling diabetes success for our customers and their health care team,” said Marc Gibeley, Head of Roche Diabetes Care North America. “It is easy-to-use and will help people with diabetes regularly check their blood glucose levels before making informed therapy and lifestyle adjustments. We look forward to its launch later this year.”

Roche Diabetes Care Roche Diagnostics GmbH

Sandhofer Straße 116

D – 68305 Mannheim

Global Communications Phone +49 621 759 9561

Fax +49 621 759789561

http://www.accu- chek.com

About the Accu-Chek Nano SmartView system

The Accu-Chek Nano SmartView blood glucose monitoring system offers a small, sleek and discreet design with easy-to-use operating buttons on top of the meter. It is the first single-strip no code meter in the Accu-Chek product family. This means it does not require any coding previously needed to calibrate the meter to the respective test strips and will use the maltose-independent Accu-Chek SmartView test strips. The Accu-Chek Nano SmartView system is part of the same product line as the Accu-Chek Aviva Nano and Accu-Chek Performa Nano systems that have already been launched successfully in many markets in the EMEA, Latin-American and APAC region.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 35 years, the Accu- Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information: www.accu-chek.com.

For more information please contact

Ute Volkmann

Roche Diabetes Care

Todd Siesky

Roche Diabetes Care

Roche Diagnostics Roche Diagnostics

Phone: +49 621 759 9561 Phone: +1 317 521 3966

E-Mail: ute.volkmann@roche.com E-Mail: todd.siesky@roche.com

or visit

www.accu-chek.com

All trademarks used or mentioned in this release are protected by law.

Gary Taubes, Author

Gary Taubes is the author of the New York Times best-sellers, Why We Get Fat and Good Calories, Bad Calories. He is a contributing correspondent for Science magazine, and a Robert Wood Johnson Foundation Independent Investigator in Health Policy Research at the University of California Berkeley School of Public Health. His articles about science, medicine and health have appeared in Discover, The Atlantic Monthly and The New York Times Magazine, among other publications. He has won three Science-in-Society Journalism Awards given by the National Association of Science Writers – the only print journalist so recognized—as well as awards from the Pan American Health Organization, the American Institute of Physics, and the American Physical Society. His writing was selected for The Best American Science Writing 2002, The Best of the Best of American Science Writing and The Best American Science and Nature Writing 2000 and 2003. He is also the author of Bad Science and Nobel Dreams. He was educated at Harvard, Stanford, and Columbia. He lives in Berkeley, California with his wife and two sons.

Listen to Diabetes Living Today® interview with Gary Taubes

January 11, 2012 ~ Medical Author Gary Taubes, of The New Your Times Best-Sellers, Why We Get Fat and Good Calories, Bad Calories.